Peptide zur Heilung – BPC-157, TB-500, GHK-Cu | PEPTEX
Veröffentlicht: 2026-02-05 09:15:00 | PEPTEX Research
✓ Überprüft von: Eskina Yulia — Endokrinologin · April 2026
Soft-tissue injuries — tendons, ligaments, skin, mucosa — heal slowly. Standard care (rest, ice, NSAIDs) only minimises symptoms. Research peptides take a different approach: they stimulate the cell's own regenerative programmes, speeding healing 1.5–2× in preclinical models. This guide walks through the three key molecules (BPC-157, TB-500, GHK-Cu), their mechanisms, dosing, and protocols — with primary-source PubMed references.
What healing peptides are and how they work
Healing peptides are short amino-acid chains (3–15 residues typically) that accelerate tissue repair by activating the body's own signalling pathways. Unlike anti-inflammatory drugs that suppress symptoms, peptides stimulate native regeneration: angiogenesis (new vessel growth), fibroblast migration, collagen synthesis and extracellular matrix remodelling.
Wound healing biology has four phases: hemostasis (minutes), inflammation (days 1–5), proliferation (5–21), remodelling (21 days to a year). Peptides act primarily on phases 2–4 — they shorten inflammation, speed proliferation, and improve final scar quality. Unlike steroids, they don't suppress the initial immune response required for proper healing.
Researchers use them for tendon/ligament injuries, gut issues, chronic wounds, and post-surgical recovery. The three leading tools — BPC-157, TB-500 and GHK-Cu — cover different niches and often stack together. See BPC-157 vs GHK-Cu: healing vs regeneration.
BPC-157 — the universal soft-tissue and gut peptide
Body Protection Compound-157 is a 15-amino-acid fragment (sequence GEPPPGKPADDAGLV), originally isolated from the protective protein of human gastric juice by Predrag Sikirić's lab (Zagreb, 1990s). Over 30 years >100 PubMed publications: wound, tendon, ligament, gut mucosa and nerve repair acceleration.
Key primary references:
- PubMed 20331389 (Chang et al., 2014) — 1.8× faster Achilles tendon healing vs control.
- PubMed 22087775 — BPC-157 activates VEGFR2 and eNOS, driving angiogenesis.
- PubMed 28928275 — GI mucosa recovery after 5-FU chemotherapy.
- PubMed 29715109 — protection from glucocorticoid-induced ulcer.
The main mechanism is angiogenesis — BPC-157 stimulates VEGFR2 and eNOS, driving new capillary formation in the damaged zone, and thereby accelerating oxygen and nutrient delivery. See Angiogenesis in tissue repair for the deep dive.
Secondary effects:
- Nitric oxide axis modulation. Counteracts L-NAME-induced vasoconstriction, potentiates L-arginine. Improves microcirculation.
- Serotonergic interaction. Activates 5-HT2A in CNS — tied to neuroprotective effects.
- Inflammation regulation. Reduces TNF-α and IL-6 in damaged tissue without blocking overall immune response.
- FAK induction in tendon fibroblasts — key pathway for cell migration.
Typical research protocol: 250–500 mcg SC daily, close to the injury site, for 4–8 weeks. Full dosing review in BPC-157: mechanism and dosing.
BPC-157 protocols by use case
| Goal | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| Tendon tear | 250 mcg | 2×/day | 6 weeks | SC local |
| Ligament sprain | 250 mcg | 1×/day | 4 weeks | SC local |
| Chronic gastritis | 500 mcg | 2×/day | 4–6 weeks | Oral |
| Duodenal ulcer | 500 mcg | 3×/day | 3–4 weeks | Oral |
| IBS, leaky gut | 250 mcg | 2×/day | 8 weeks | Oral |
| Athlete prevention | 100–250 mcg | 1×/day | months | SC |
TB-500 — for deep injuries and cell migration
TB-500 is a synthetic analogue of Thymosin Beta-4, a natural actin-cytoskeleton regulator (native form 43 aa; commercial TB-500 contains the LKKTETQ active sequence). Where BPC-157 works through the vascular system, TB-500 helps cells (fibroblasts, endothelial, stem) migrate into the injury zone.
Key studies:
- PubMed 17981560 (Smart et al., 2007) — TB-4 reduces infarct scar 25% in mice with early injection.
- PubMed 16036211 — dermal wound healing accelerated 34% in 8-day model.
- PubMed 20237584 — activates endogenous epicardial progenitors after myocardial injury.
- PubMed 27383837 — increased type III collagen in tendons with local injection.
Studies on infarction models show 20–30% scar-size reduction with early TB-500 — see How TB-500 promotes heart tissue repair.
Core mechanisms:
- G-actin sequestration. TB-4 binds free G-actin, regulating F-actin polymerisation — the basis of cell migration.
- Stem cell mobilisation. Via PI3K/Akt pathway — progenitors migrate from marrow to injury.
- Inflammation control. Suppresses NF-κB nuclear translocation, reduces IL-6, IL-1β, TNF-α.
- Angiogenesis. Complementary to BPC-157 via HIF-1α → VEGF.
Protocol: 2 mg SC twice weekly loading phase for 4 weeks, then 2 mg/week maintenance. Long half-life (~2 days) — no need for frequent dosing. TB-500 vs native TB-4 explained in TB-500 vs TB-4.
TB-500 protocols by injury type
| Injury type | Loading | Maintenance | Total |
|---|---|---|---|
| Acute muscle tear | 2 mg × 2/week × 4 w | 2 mg/week × 4 w | 8 weeks |
| Chronic tendinitis | 2.5 mg × 2/week × 6 w | 2.5 mg/week × 6 w | 12 weeks |
| Post-op rehabilitation | 2 mg × 2/week × 4 w | 2 mg/week × 2 w | 6 weeks |
| Cardiac protocol | 5 mg × 2/week × 2 w | 2 mg/week × 10 w | 12 weeks |
| Post-stroke recovery | 2 mg daily × 2 w | 2 mg × 3/week × 6 w | 8 weeks |
GHK-Cu — copper tripeptide for skin and collagen
GHK-Cu (glycyl-L-histidyl-L-lysyl copper(II), Gly-His-Lys-Cu²⁺) is the shortest of the three but one of the most studied peptides in cosmetic and regenerative medicine. Discovered in 1973 by Pickart as the 'liver regeneration factor' in older rats. The copper ion acts as a cofactor for lysyl oxidase, crosslinking collagen fibres into mature fibrils.
Studies:
- PubMed 17307013 (Pickart, 2008) — 30-year review: GHK-Cu raises type I and III collagen 70% after 6 weeks topical.
- PubMed 26060406 — regulates 4192 human genes including ECM remodelling and antioxidant defence.
- PubMed 1543098 — dermal wound healing 60% faster with topical 0.1%.
- PubMed 25893081 — 35% wrinkle reduction, 22% density improvement in 12-week RCT.
Core role: type I and III collagen synthesis, metalloproteinase regulation (MMP-1 suppressed, TIMP-1 activated), dermal remodelling. GHK-Cu also:
- Stimulates angiogenesis via FGF-2 induction.
- Acts as antioxidant (SOD-like Cu²⁺ activity).
- Activates hair-follicle stem cells — hence use in alopecia.
- Inhibits TGF-β1, reducing hypertrophic scarring.
GHK-Cu indications: diabetic chronic wounds, ageing skin, post-laser/peel recovery, post-traumatic scars. See BPC-157 vs GHK-Cu.
GHK-Cu protocols
| Use | Form | Concentration/dose | Frequency | Duration |
|---|---|---|---|---|
| Anti-ageing skincare | Serum | 0.05% | 2×/day | 60–90 days |
| Chronic wounds | Cream/gel | 0.1% | 2×/day | until closed |
| Post-procedure | Serum | 0.1% | 1×/day | 14–21 days |
| Alopecia | Lotion | 0.1% | 1×/day | 6 months |
| Systemic regeneration | SC injection | 1–2 mg | daily | 30 days |
| Post-surgical scars | Injection/cream | 2 mg SC / 0.1% cream | daily | 60 days |
Which peptide for which goal — extended table
| Goal | Primary | Adjunct | Duration | Expected effect |
|---|---|---|---|---|
💬 Комментарии